Emergent BioSolutions EBS
NYSE EBS
$6.11 -0.25 (-3.93%)
As of: Oct 20, 2026 · 9:34 AM EDT

Emergent BioSolutions (EBS) Short-Term Debt issuances (2019)

Updated

Emergent BioSolutions (EBS) reported Short-Term Debt issuances of $100 million for Q2 2019, up 233.3% from the prior quarter.

Analysis

Emergent BioSolutions (EBS) Short-Term Debt issuances (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Issuance (Qtr)
1 Eli Lilly 1,143.87 Bn 1,112.46 Bn 19.71 Bn -
2 Johnson & Johnson 621.90 Bn 540.43 Bn 17.26 Bn 707.00 Mn
3 AbbVie 507.81 Bn 480.92 Bn 12.70 Bn -
4 Merck 364.52 Bn 318.90 Bn 12.21 Bn -
5 Novartis Ag 295.78 Bn 259.77 Bn 11.24 Bn -
6 Astrazeneca 259.85 Bn 233.54 Bn 12.86 Bn -
7 Amgen 231.44 Bn 186.84 Bn 7.24 Bn -
8 Gilead Sciences 193.87 Bn 168.07 Bn 6.22 Bn -
9 Pfizer 170.66 Bn 117.30 Bn 10.94 Bn -
10 Emergent BioSolutions 323.07 Mn -427.83 Mn 137.20 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 100.00 Mn
Mar 31, 2019 30.00 Mn
API Access

Emergent BioSolutions Short-Term Debt issuances API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-issuances&ticker=EBS&period=max&api_key=YOUR_API_KEY